Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Brander who wrote (2878)	3/20/1998 4:43:00 PM
From: Hank	Read Replies (2) \| Respond to of 7041

Yes, but the efficacy is not necessarily the same for each individual patient. What works on one person may not work on another. Yet, the overall percentage of positive results within a given population may be identical for each drug. Another example would be anithypertensives. The reason there are so many is because the individuals response to these drugs varies widely. I believe I pointed out that Vasomax stood a chance of approval if it could be proven to work on individuals that do not respond to Viagra. In the end, it has to be proven that it works all and that hasn't been conclusively established. Any new drug that is submitted to the FDA for approval must demonstrate that it is in some respects better than what is currently available on the market. If you don't believe me, then go the FDA's home page and see if you can find an e-mail address to write to and ask them.